Get the Daily Brief
Latest Biotech News
Repertoire lands Lilly’s $1.9bn autoimmune pact
Repertoire Immune Medicines signed a high‑value partnership with Eli Lilly to develop tolerizing therapies for multiple autoimmune diseases. The deal includes an $85 million upfront payment, up to...
Phase III fizzle... Quince collapses
Quince Therapeutics announced top‑line results from its pivotal Phase III Neat trial testing monthly dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) for...
FDA drafts myeloma guidance: MRD favored for accelerated approvals
The FDA issued draft guidance advising sponsors developing multiple myeloma therapies to use minimal residual disease (MRD) negativity as a key endpoint for accelerated approval pathways. The...
Grail submits Galleri multi‑cancer test to FDA for PMA
Grail filed a premarket approval (PMA) submission for its Galleri multi‑cancer early detection test, centering the dossier on performance and safety data from more than 25,000 participants in...
DeepMind launches AlphaGenome: predicts regulatory variant effects
Google DeepMind published AlphaGenome, a sequence‑based model that predicts regulatory effects of non‑coding genomic variants across long DNA contexts up to one million base pairs. The model...
Corcept says FDA warned it — regulatory dispute surfaces
Two reports surfaced about Corcept Therapeutics’ failed submission for a Cushing’s syndrome drug: the company received a complete response letter, and the FDA stated the agency had flagged serious...
AstraZeneca bets on China: $15bn push and $1.2bn CSPC obesity pact
AstraZeneca expanded its China play with two coordinated moves: a broad investment commitment and a targeted licensing pact. The company agreed a strategic collaboration with CSPC that pays $1.2...
Illumina closes SomaLogic buy: proteomics scales inside NGS ecosystem
Illumina completed its acquisition of SomaLogic and related assets, paying $350 million in cash plus contingent milestones and royalties. The transaction brings SomaLogic’s SomaScan aptamer‑based...
NanoMosaic wins FDA AMT nod: gene therapy QC tech prioritized
The FDA granted Advanced Manufacturing Technology (AMT) designation to NanoMosaic’s Nanoneedle platform for multiplex testing of AAV vector genome and capsid titers. The designation gives...
Tenpoint’s presbyopia win: FDA clears dual‑agent drop and backstops launch with $235M
Tenpoint Therapeutics secured FDA approval for Yuvezzi, the first dual‑agent ophthalmic drop for presbyopia combining carbachol and brimonidine. The clearance positions Tenpoint against...
Phase‑III miss implodes Quince: steroid therapy for A‑T abandoned
Quince Therapeutics halted development of its lead eDSP (dexamethasone encapsulated in autologous erythrocytes) program after its pivotal NEAT Phase III in ataxia‑telangiectasia failed to meet...
Lilly taps Repertoire: $1.92bn alliance to decode and treat autoimmunity
Eli Lilly struck a deal with Repertoire Immune Medicines to develop tolerizing therapies for autoimmune diseases, a collaboration structured with an $85 million upfront payment and up to $1.84...
Grail files Galleri for FDA PMA: large prospective datasets underpin bid
Grail submitted a premarket approval application to the FDA for its Galleri multi‑cancer early detection test, relying on performance and safety data from more than 25,000 participants in the...
DeepMind’s AlphaGenome: long‑context model decodes regulatory variants
DeepMind published AlphaGenome, a long‑sequence DNA model that predicts regulatory effects of non‑coding variants across up to one million base pairs. The Nature paper shows the model can infer...
Beckman–Automata tie-up: Danaher strategic backing, $45M Series C to scale lab automation
Beckman Coulter Life Sciences and Automata announced a strategic partnership integrating Beckman liquid‑handling and analytic instrumentation into Automata’s LINQ AI‑ready automation ecosystem;...
Thermo Fisher raises 2026 outlook: mid‑single digit growth expected after strong quarter
Thermo Fisher reported stronger‑than‑expected Q4 results and gave 2026 guidance calling for roughly 4–6% revenue growth, driven by life‑science solutions and laboratory products. The company...
AstraZeneca’s China bet: $1.2B CSPC obesity pact and $15B China push
AstraZeneca agreed a $1.2 billion upfront licensing deal with China’s CSPC and outlined a sweeping China strategy, doubling down on obesity and metabolic medicines. The CSPC pact gives AZ rights...
Illumina snaps up SomaLogic: proteomics meets sequencing
Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools, paying $350 million in cash and taking on near‑term milestones and royalties. The deal folds SomaLogic’s...
FDA backs NanoMosaic: AMT designation for gene therapy QC
The FDA granted NanoMosaic an Advanced Manufacturing Technology (AMT) designation for its Nanoneedle/Tessie platform that measures AAV vector genome integrity and capsid titers during gene therapy...
Lab automation scales: Beckman pairs with Automata; Automata nets $45M
Beckman Coulter Life Sciences announced a strategic partnership with Automata to integrate Beckman liquid‑handling, genomic and cell‑analysis instruments into Automata’s AI‑ready LINQ automation...